|
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme Clinical research trials and Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme. Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme clinical trial. Subjects frequently obtain the most expert healthcare possible for their Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme  Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme
For Condition: Atherosclerosis,Coronary Disease
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This substance functions to keep blood vessels relaxed and to prevent blood from clotting inside the vessels. Studies done by researchers in the Cardiology Branch of the National Heart, Lung and Blood Institute have shown that nitric oxide activity may be lower in patients with hardening of the arteries (atherosclerosis) and risk factors for atherosclerosis. Another substance released by the cells of the endothelium is called bradykinin. It functions to stimulate the production of nitric oxide. Therefore bradykinin is also responsible for the relaxation and widening of blood vessels. An enzyme found in the blood called angiotensin-converting enzyme (ACE) inactivates baradykinin and thereby decreases the production of nitric oxide. The activity of ACE is determined by genetics and is different in each person. Medications that block ACE (ACE-inhibitors) may be useful for patients with high levels of ACE activity. This study is designed to determine; 1. The role of bradkinin in stimulating the production of nitric oxide 2. Whether ACE-inhibitors improve blood vessel relaxation caused by bradykinin 3. Whether ACE-inhibitors improve abnormal blood vessel relaxation 4. Whether ACE-inhibitors and bradykinin affect blood clotting 5. Whether blood vessel response to ACE-inhibitor and bradykinin depends on the patients genetic make-up
Details: The vascular endothelium tonically releases nitric oxide that produces smooth muscle relaxation, inhibition of platelet aggregation, and inhibition of cellular proliferation. Studies in the Cardiology Branch have demonstrated that nitric oxide activity is reduced in the coronary and peripheral vasculature of patients with atherosclerosis and in those with risk factors for atherosclerosis. Bradykinin, an endothelium-dependent vasodilator, may be an important modulator of vascular tone in vivo because it is tonically produced by the endothelium. Bradykinin is inactivated by angiotensin converting enzyme (ACE) that is found on the endothelial cell surface. The activity of plasma ACE is variable among individuals and is at least partly genetically determined. ACE activity may modulate the local vascular effects of bradykinin, and thus, ACE inhibitors would be expected to improve endothelium-dependent responses in patients with higher tissue ACE activity. This protocol is designed to determine 1) the role of bradykinin in stimulating nitric oxide release in the human coronary and peripheral vasculature; 2) whether ACE inhibitors improve bradykinin-induced vasodilation, and if so, whether this occurs as a result of endothelium-dependent release of nitric oxide; 3) whether ACE inhibitors improve the abnormal shear-induced coronary vasodilation in patients with normal coronary arteries and those with coronary artery disease; 4) whether ACE inhibitors and bradykinin affect platelet function; 5) whether the vascular responses to ACE inhibition and bradykinin depend on the ACE genotype.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Anyone with chest pain with known or suspected coronary artery disease.
Total Enrollment: 209
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950099; 95-H-0099
Study Start Date: March 29, 1995
Record last reviewed: April 28, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001461
Other Coronary Disease Studies:
1. Gender Response To Coronary Risk
2. Heart Disease Risk Factors in African Americans
3. Beta-Blocker Heart Attack Trial (BHAT)
4. Homocyst(e)ine, Vitamin Status, and CVD Risk
5. Study of Blood Flow in Heart Muscle
Related Studies:
Other Coronary Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme
|
|
|
|
|
|
|
|
